Pharmaceutical Executive Europe - November/December 2007 - (Page 41) Pharmaceutical Executive Europe Nov/Dec 2007 M&A 41 short intervals, should also consider creating an institutionalised integration team. In many cases, however, only the pre-merger and deal processes are institutionalised. The actual integration is then left to the functional departments, which need to fulfil this task in addition to everyday operations and their contribution to the due diligence teams — and are thus overburdened. About the Authors Wolfram Heinisch, vice president, STADA Arzneimittel AG, led the company’s largest integration programme — the takeover of Hemofarm. (wolfram.heinisch@stada.de) Management hubris Takeovers often run the risk of losing focus on the integration activities quickly in favour of identifying a new acquisition target. Well-managed companies know that a takeover can only be called successful and celebrated once the integration and synergy realisation are completed. Often, management neglects integrating the new subsidiary and turns to a new acquisition target, as acquiring is comparatively easier than integrating. Closing deals can be celebrated but job losses and political issues during the integration process are a nuisance. The more management concentrates solely on closing the deal simply by accepting excessive purchasing prices, the more difficult it tends to be to realise any synergies. ■ Matthias Dutschmann, principal consultant, Capgemini Consulting Germany, has worked in the consulting industry for seven years and has managed several strategy and postmerger integration projects in the pharmaceutical and generics industries. (Matthias.dutschmann@capgemini.com) Tel. +49 162 234 3692 Employed in an FDA-regulated industry? You need these journals! Advanstar Communications Inc (publisher of LCGC Europe, Pharmaceutical Technology Europe and other industry-related publications) presents two journals written and designed to help you stay current with validation and compliance trends. The JOURNAL OF VALIDATION The JOURNAL OF GXP COMPLIANCE TECHNOLOGY presents an objective delivers practical approaches for forum for the dissemination of implementing compliance strategies. information to professionals in FDAPeer-reviewed and dedicated to regulated industries. Articles have expanding the global knowledge base been thoroughly researched, reflect for professionals in FDA-regulated current industry standards, and are industries, the Journal of GXP not promotional in nature, making Compliance remains the industry’s this the industry’s primary source of primary source of compliance validation information. information. 91% of your peers state that the Journal of Validation 95% of your peers state that the Journal of GXP Compliance Technology is an authoritative source that keeps them abreast is an authoritative source that keeps them abreast of current of current validation trends.* compliance issues.* *2006 Readership Study conducted by Advanstar Research Each journal subscription (1 year/4 issues) is $262. Save by ordering two years for just $478! Subscribe online at www.gxpandjvt.com Or contact IVT Customer Service by phone: 1-218-740-7028 To order by fax, send details and payment method to 1-218-740-6417 ©2007 Advanstar Communications DINS http://www.gxpandjvt.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.